Free Trial
NASDAQ:CLGN

CollPlant Biotechnologies Q1 2023 Earnings Report

CollPlant Biotechnologies logo
$2.18 +0.06 (+2.83%)
Closing price 05/1/2025 03:50 PM Eastern
Extended Trading
$2.17 -0.01 (-0.23%)
As of 05/1/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CollPlant Biotechnologies EPS Results

Actual EPS
-$0.33
Consensus EPS
-$0.29
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

CollPlant Biotechnologies Revenue Results

Actual Revenue
$0.43 million
Expected Revenue
$0.24 million
Beat/Miss
Beat by +$190.00 thousand
YoY Revenue Growth
N/A

CollPlant Biotechnologies Announcement Details

Quarter
Q1 2023
Time
N/A
Conference Call Date
Wednesday, May 24, 2023
Conference Call Time
8:00AM ET

Upcoming Earnings

CollPlant Biotechnologies' Q1 2025 earnings is scheduled for Tuesday, May 27, 2025, with a conference call scheduled on Friday, May 23, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

CollPlant Biotechnologies Earnings Headlines

CollPlant provides corporate update
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
See More CollPlant Biotechnologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CollPlant Biotechnologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CollPlant Biotechnologies and other key companies, straight to your email.

About CollPlant Biotechnologies

CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.

View CollPlant Biotechnologies Profile

More Earnings Resources from MarketBeat